



N 09/703,350

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MEHRABAN ET AL. Examiner: G. NICKOL
Serial No.: 09/703,350 Group Art Unit: 1642
Filed: OCTOBER 31, 2000 Docket No.: 11669.213USU1
Confirmation No.: 3065 Customer No.: 23552
Title: DIFFERENTIALLY EXPRESSED GENES INVOLVED IN
ANGIOGENESIS, THE POLYPEPTIDES ENCODED THEREBY,
AND METHODS OF USING THE SAME

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 408488347 US
Date of Deposit: September 2, 2004

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Mail Stop RCE, P.O. Box 1450, Alexandria, VA 22313-1450.

By:

Sheryl A. Boerboom
Name: Sheryl A. Boerboom

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.




Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: September 2, 2004

Katherine M. Kowalchyk
Katherine M. Kowalchyk
Reg. No. 36,848


INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.213USU1

Application Number:

09/703,350

Applicant: MEHRABAN ET AL.

Filing Date: 10/31/00

Group Art Unit: 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Davis, G. et al., "An $\alpha 2\beta 1$ Integrin-Dependent Pinocytic Mechanism Involving Intracellular Vacuole Formation and Coalescence Regulates Capillary Lumen and Tube Formation in Three-Dimensional Collagen Matrix", <u>Experimental Cell Research</u> , 224:39-51 (1996)
		Filvaroff, E. et al., "Stanniocalcin 1 Alters Muscle and Bone Structure and Function in Transgenic Mice", <u>Endocrinology</u> , 143(9):3681-3690 (2002)
		Kahn, J. et al., "Gene Expression Profiling in an <i>in Vitro</i> Model of Angiogenesis", <u>American Journal of Pathology</u> , 156(6):1887-1900 (June 2000)
		Presta, L. et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders", <u>Cancer Research</u> , 57:4593-4599 (Oct. 15, 1997)
		Wary, K. et al., "Analysis of VEGF-responsive Genes involved in the activation of endothelial cells", <u>Molecular Cancer</u> , 2:25 (July 9, 2003)
		Zlot, C. et al., "Stanniocalcin 1 is an Autocrine Modulator of Endothelial Angiogenic Responses to Hepatocyte Growth Factor", <u>The Journal of Biological Chemistry</u> , 278(48):47654-47659 (Nov. 28, 2003)

23552

PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

APPLICANT: Mehraban et al.

ATTORNEY DOCKET NO:

09800081-0041

SERIAL NO. 09/703,350

GROUP ART UNIT: 1642

FILING DATE: October 31, 2000

EXAMINER: Gary B. Nickol

INVENTION: "DIFFERENTIALLY EXPRESSED GENES INVOLVED IN
ANGIOGENESIS, THE POLYPEPTIDES ENCODED THEREBY, AND
METHODS OF USING THE SAME"

Hon. Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with the provisions of 37 C.F.R. § 1.56, Applicants request that citation and examination of the references identified on the attached PTO-1449 form, copies of which are enclosed herewith in accordance with 37 C.F.R. § 1.98, be made during the course of examination of the above-referenced application for United States Letters Patent.

I. SUBMITTED UNITED STATES PATENT REFERENCES

<u>Reference</u>	<u>Number</u>	<u>Patentee</u>	<u>Issue Date</u>
		NONE	

II. SUBMITTED FOREIGN PATENT REFERENCES

<u>Reference</u>	<u>Number</u>	<u>Country</u>	<u>Date of Publication</u>
AA	WO 93/23075	PCT	November 25, 1993
AB	WO 97/30065	PCT	August 21, 1997
AC	WO 98/31709	PCT	July 23, 1998
AD	WO 00/52051	PCT	September 8, 2000
AE	WO 00/55174	PCT	September 21, 2000
AF	WO 01/73025	PCT	October 4, 2001

III. OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS


AG Eddie Kohfeldt et al., "Nidogen-2: A New Basement Membrane Protein with Diverse Binding Properties," Journal of Molecular Biology, Vol. 282, 1998, Pg. 99-109, ISSN: 0022-2836.

AH Ian N. Bird et al., "Homophilic PECAM-1 (CD31) interactions prevent endothelial cell apoptosis but do not support cell spreading or migration," Journal of Cell Science, Vol. 112, No. 12, June 1999, Pg. 1989-1997, ISSN: 0021-9533.

REMARKS

References AA, AB, AC, AD, AE, AF, AG and AH were cited in International Search Report of July 2, 2002 in counterpart International Application No: PCT/US00/30051. A copy of the International Search Report is submitted herewith.

Submitted by,

 (Reg. 48,492)
Gregory M. Zinkl, Ph.D.

SONNENSCHN NATH & ROSENTHAL

P.O. Box 061080

Wacker Drive Station

Sears Tower

Chicago, IL 60606-1080

Telephone: 312/876-8000

Agent for Applicant(s)

Form PTO-1449
(Rev. 8-88)

Attorney Docket No. 9800081-0041

Serial No. 09/703,350

Applicant: Fuad Mehraban et al.

Filing Date: October 31, 2000

Group: 1642

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Initial*	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS

		Document Number	Date	Name	Class	Subclass	Translation	
							Yes	No
	AA	WO 93/23075	Nov. 25, 1993	Liang et al.			X	
	AB	WO 97/30065	Aug. 21, 1997	Falb			X	
	AC	WO 98/31709	July 23, 1998	Gerl				X
	AD	WO 00/52051	Sept. 8, 2000	Stilz			X	
	AE	WO 00/55174	Sept. 21, 2000	Ruben			X	
	AF	WO 01/73025	Oct. 4, 2001	Kalluri			X	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

- AG Eddie Kohfeldt et al., "Nidogen-2: A New Basement Membrane Protein with Diverse Binding Properties," Journal of Molecular Biology, Vol. 282, 1998, Pg. 99-109, ISSN: 0022-2836.
- AH Ian N. Bird et al., "Homophilic PECAM-1 (CD31) interactions prevent endothelial cell apoptosis but do not support cell spreading or migration," Journal of Cell Science, Vol. 112, No. 12, June 1999, Pg. 1989-1997, ISSN: 0021-9533.

14126335



S/N 09/703,350

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MEHRABAN ET AL. Examiner: G. NICKOL
Serial No.: 09/703,350 Group Art Unit: 1642
Filed: OCTOBER 31, 2000 Docket No.: 11669.213USU1
Confirmation No.: 3065 Customer No.: 23552
Title: DIFFERENTIALLY EXPRESSED GENES INVOLVED IN
ANGIOGENESIS, THE POLYPEPTIDES ENCODED THEREBY,
AND METHODS OF USING THE SAME

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 371503772 US
Date of Deposit: May 24, 2005

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Mail Stop Amendment, Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450.

By: 

Name: Sheryl A. Boerboom

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
(37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Enclosed is a check in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.



Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: May 24, 2005


Katherine M. Kowalchuk
Reg. No. 36,848

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.213USU1	Application Number: 09/703,350
	Applicant: MEHRABAN ET AL.	
	Filing Date: 10/31/00	Group Art Unit: 1642

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,365,572 B1	04/02/02	STILZ ET AL.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Gerritsen et al., "Stanniocalcin: No Longer Just a Fish Tale", <i>Vitamins and Hormones</i> , 70:105-135 (2005)

23552
PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	